KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Kairos Pharma, LTD.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.57−0.03 (-5.19%)
Close on Oct 19, 2026
- Market cap
- $12.21M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Kairos Pharma's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John S. Yu | CEO and Chairman, Director, 10% owner | 5,546,677 | 23.41% | Nov 26, 2025 |
| Neil Bhowmick | Chief Scientific Officer | 1,311,739 | 5.54% | Dec 30, 2025 |
| Doug Samuelson | Chief Financial Officer | 293,039 | 1.24% | Nov 26, 2025 |
| Ramachandran Murali | VP of Research and Development | 299,529 | 1.26% | Nov 26, 2025 |
| Hyun W. Bae | Director | 73,370 | 0.31% | Dec 23, 2025 |
| Rahul Singhvi | Director | 49,204 | 0.21% | Nov 26, 2025 |
| Hansoo Michael Keyoung | Director | 29,084 | 0.12% | Nov 26, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Neil Bhowmick Chief Scientific Officer | Oct 8, 2025 | Award | +171,756 | – | – | 1,311,739 |
| Hyun W. Bae Director | Oct 8, 2025 | Award | +19,084 | – | – | 73,370 |
| Rahul Singhvi Director | Oct 8, 2025 | Award | +19,084 | – | – | 49,204 |
| Hansoo Michael Keyoung Director | Oct 8, 2025 | Award | +19,084 | – | – | 29,084 |
| Doug Samuelson Chief Financial Officer | Oct 8, 2025 | Award | +152,672 | – | – | 293,039 |
| Ramachandran Murali VP of Research and Development | Oct 8, 2025 | Award | +152,672 | – | – | 299,529 |
| John S. Yu CEO and Chairman, Director, 10% owner | Oct 8, 2025 | Award | +190,840 | – | – | 230,105 |
| Hyun W. Bae Director | Sep 16, 2025 | Award | +10,000 | – | – | 54,286 |
| Hansoo Michael Keyoung Director | Sep 16, 2025 | Award | +10,000 | – | – | 10,000 |
| Neil Bhowmick Chief Scientific Officer | Jan 1, 2025 | Award | +14,000 | – | – | 1,139,983 |
| John S. Yu CEO and Chairman, Director, 10% owner | Jan 1, 2025 | Award | +14,000 | – | – | 5,355,838 |
| Ramachandran Murali VP of Research and Development | Jan 1, 2025 | Award | +14,000 | – | – | 147,057 |
| Ramachandran Murali VP of Research and Development | Nov 25, 2024 | Buy | +200 | $1.59 | $318 | 133,057 |
| Doug Samuelson Chief Financial Officer | Nov 22, 2024 | Buy | +2,500 | $1.50 | $3.75K | 60,796 |
| John S. Yu CEO and Chairman, Director, 10% owner | Nov 20, 2024 | Buy | +4,000 | $1.44 | $5.76K | 5,341,837 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.